Selinexor with azacitidine and venetoclax for new AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18 or older) with newly diagnosed AML
- Your doctor says you are not a good candidate for intensive chemotherapy, or you refuse it
- You have either age 75+ or specific health issues that make intensive chemotherapy unsafe (such as heart, lung, or kidney problems, or lower activity level)
- Your liver and kidney tests meet the study limits (for example, enough kidney function and acceptable bilirubin/AST/ALT levels)
- You have not had prior AML treatment (except hydroxyurea for symptom control)
- You do not have certain infections or brain involvement from AML (no known HIV, active hepatitis B/C, or AML in the central nervous system)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2 study tests whether doctors can choose the best AML treatment plan using a special blood/marrow test done on day 14. It may help people who are not good candidates for intensive chemotherapy by adjusting therapy based on early response.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination can help control the disease, especially before a stem cell transplant.
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.